Carl Zeiss Meditec, Inc.

The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements. DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS enters the U.S. market at a time when more than 8 million eyes have been treated with SMILE worldwide, reflecting the technology's broad global momentum driven by strong adoption in Asia and Europe. Continue Reading VISUMAX 800 with SMILE pro software from ZEISS "The increasing global adoption of SMILE from ZEISS represents the positive impact the small incision lenticule extraction procedure continues to have on the quality of life for patients," said Andrew Chang, Head of Global Sales for ZEISS Medical Technology. "With the availability of the ZEISS SMILE pro software module in the U.S. market, surgeons can now offer the latest refractive technology to help expand their business and provide excellent outcomes for patients." "ZEISS continues to set itself apart in the U.S. market with the availability of the VISUMAX 800 with SMILE pro software from ZEISS, providing the latest digital technology from the company's legacy of innovation to meet the evolving needs of refractive surgeons," said Euan S. Thomson, Ph.D., President of Ophthalmology Strategic Business Unit and Head of the Digital Business Unit for ZEISS Medical Technology. "As part of the ZEISS Medical Ecosystem, this next generation femtosecond laser system creates data-driven insights to help surgeons manage better treatment paths for patients while supporting each surgeon's unique practice requirements for greater workflow efficiency and performance." The VISUMAX® 800 with SMILE® pro software from ZEISS enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.* Additionally, the shorter procedure time can reduce stress for surgeons and their patients. The ZEISS femtosecond laser also provides greater flexibility for the surgeon and patient, with a smaller footprint and compatibility with a variety of patient beds, adapting to the clinical environment to provide cutting-edge technology without compromise. With the availability of the VISUMAX® 800 with SMILE® pro software from ZEISS in the U.S., surgeons can utilize a number of workflow enhancements including: the CentraLign® centration aid, a computer-controlled function for easy centration; the OcuLign® cyclotorsion adjustment to help counter cyclotorsion that may occur; and VISULYZE user nomograms to help surgeons collect and analyze patient data, while also providing detailed nomograms and enabling more control during every surgery. With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons. "The VISUMAX 800 is a practice builder and allows surgeons to differentiate their practice from local competitors," said Luke Rebenitsch, MD, at ClearSight LASIK and 43Vision, in Oklahoma City, Oklahoma, USA. For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit . * Data on file, myopia with optical zone 6.5 mm. Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. Contact for investors: Sebastian Frericks Head of Group Finance & Investor Relations Carl Zeiss Meditec AG Phone: +49 3641 220 116 Mail: [email protected] Contact for the press: Frank Smith Head of Global Communications Ophthalmic Devices Carl Zeiss Meditec Inc. Phone: +49 3641 220 331 Mail: [email protected] Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: SOURCE Carl Zeiss Meditec AG

JENA, Deutschland and INGELHEIM, Deutschland, Oct. 2, 2023 /PRNewswire/ -- ZEISS Medical Technology and Boehringer Ingelheim announce today a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with serious eye diseases. The partnership brings together their leading expertise in ophthalmological technology, data analytics, algorithms and the development of first-in-class treatments to detect early and treat retinal diseases before irreversible vision loss occurs. Continue Reading ZEISS Medical Ecosystem Boehringer Ingelheim logo More than 300 million people worldwide are at risk today of losing their eyesight due to diseases leading to functional loss of the retina.* The number of people suffering from vision loss is rising due to aging populations and widening health inequity gaps. Undiagnosed and untreated retinal diseases have a profound impact on people's lives, potentially leading to isolation, loss of independence, depression and reduced quality of life. Unfortunately, diagnosis often occurs too late to prevent vision loss, and for many conditions, no treatment is available at all. The new partnership will focus on identifying markers of early stages of retinal diseases by leveraging ZEISS Medical Technology's cloud-connected devices and AI-assisted analysis of massive image data sets. This will provide a basis for clinical studies for development of more personalized and precise treatments of early stages of chronic retinal disease as well as earlier detection and prediction capabilities to preserve vision through new treatment pathways. "At ZEISS, we have long understood that where collaboration thrives, innovation emerges," said Euan S. Thomson, Ph.D., Head of the Ophthalmology Strategic Business Unit and Head of the Digital Business Unit for ZEISS Medical Technology. "With our announcement today with Boehringer Ingelheim, we're building on our strategy to innovate through partnerships in order to make breakthrough discoveries to combat vision loss and improve people's lives. Enabled by our ZEISS Medical Ecosystem and the platform's ability to aggregate massive data sets for analysis, we're strongly positioned to establish new partnerships in pursuit of research yet to be investigated, to accelerate access to future technologies and markets, and to help clinicians provide earlier detection and more personalized and precise care for their patients." "Our partnership with ZEISS Medical Technology will allow us to develop precision therapies delivering the right treatment for the right patient at the right time to prevent vision loss by intervening before irreversible damage occurs. It is part of our commitment to champion early detection and treatment and will contribute to transforming the lives of people with serious eye disease," said Ulrike Graefe-Mody, Ph.D., Head of Retinal Health at Boehringer Ingelheim. As a leading pioneer of science in optics for more than 100 years, ZEISS's medical expertise and digital leadership is foundational to the ZEISS Medical Ecosystem and its digitally connected workflows, which are generating millions of data points every day. This connected and secure architecture integrates diagnostic and therapeutic devices supported by a cloud-based platform in which data aggregation, automation and AI analytics can be harnessed to help drive new discoveries to address the clinical challenges facing healthcare professionals and ophthalmologists today. The ZEISS Medical Ecosystem is powered by the ZEISS Health Data Platform, designed to facilitate massive data aggregation at scale, enabling new forms of partnerships focused on leveraging that data to generate new, transformative insights. Boehringer Ingelheim has a leading understanding of disease biology aiming at a paradigm change in retinal health through earlier detection and intervention to achieve meaningful improvements in patient outcomes. Over the past decade, Boehringer Ingelheim has built a diverse pipeline, which focuses on three priority areas to address retinal conditions – the preservation of vascular function, targeting inflammation and neuroprotection. * World Health Organization, World Report on Vision, Executive Summary, October 8, 2019, Not all products, services or offers are approved or offered in every market and approved labelling and instructions may vary from one country to another. For country specific product information, see the appropriate country website. Contact for investors: Sebastian Frericks Head of Group Finance & Investor Relations Carl Zeiss Meditec AG Phone: +49 3641 220 116 [email protected] Contact for the press: Frank E. Smith Head of Global Communications Ophthalmology Carl Zeiss Meditec Inc. Phone: +1 925 487 3036 [email protected] About Carl Zeiss Meditec AG Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,224 employees worldwide, the Group generated revenue of €1,902.8m in fiscal year 2021/22 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. About Boehringer Ingelheim Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at    SOURCE Carl Zeiss Meditec AG

▎药明康德内容团队报道8月3日，由人民日报健康客户端、健康时报联合主办的第十四届健康中国论坛发布了备受业内关注的十大医疗器械等系列榜单。据悉，第十四届健康中国论坛榜单工作自2021年10月7日启动以来，历时7个多月，分别成立了榜单顾问委员会、学术委员会、榜单工作小组等相关工作机构，制定了各榜单入选标准。榜单工作小组通过业界专家推荐、行业访谈、资料查证等方式，广泛征求意见，遵照参评标准，形成候选榜单。经过学术委员会评议、网络公示投票等环节，最终确定榜单结果并在论坛上发布。其中，十大医疗器械榜单根据创新性、突破性、影响力等指标评选。本文将结合公开资料，对这些创新医疗器械做简单介绍，供读者参阅。截图来源：参考资料[1]产品名称：uMR Omega 3.0T 磁共振成像系统研发机构：联影医疗获批时间：2021年4月入选评语：世界上首款75厘米超大孔径3.0T磁共振系统，提升30%磁体腔内空间，实现全身百秒内成像。uMR Omega 3.0T磁共振，以毫厘间的精进，实现行业新突破！据联影医疗新闻稿介绍，相较于业界主流60cm标准孔径磁共振，uMR Omega孔径扩大至75cm，可容纳600斤的超重患者，亦能为肩部、肘部、髋关节等远离人体中心部位的磁共振检查开辟更加广泛的应用空间，使大体型、幽闭恐惧症患者以及极端肥胖人群、孕妇、佝偻症等其他特殊检查需求人群拥有了更多的选择。产品名称：MAZOR X 脊柱外科智能导航机器人研发机构：美敦力（Medtronic）获批时间：2021年4月入选评语：18年临床经验，5.5万多例手术，解决传统脊柱手术“看不清”“打不准”“想不全”的难题。MAZOR X 机器人，骨科手术精准、高效、安全的新标杆！据美敦力公开资料介绍，MAZOR X用于脊柱外科手术，可以帮助医生减少侵入性操作、提高手术的可预见性和精准性。它具体有以下特点：1）通过美敦力核心算法的解剖洞察引擎技术，以及基于3D数据的AI术前计划系统，可以突破传统手术的局限，为医生提供全局术前规划；2）拥有全程可视化导航，手术期间可以实时追踪手术工具和植入物，并显示在屏幕上，相当于使医生开着“透视眼”做手术；3）一体式患者随动平台可以确保“患者—手术床—机械臂”三位一体，避免手术期间外力所引起的患者移动，提高操作平台的整体稳定性与精确性。产品名称：AXIOS电切引流支架研发机构：波士顿科学（Boston Scientific）获批时间：2021年6月入选评语：全球首款用于超声内镜引导下的腔内治疗支架，解决方案连续三年荣获盖伦奖提名。AXIOS电切引流支架，开启从诊断到治疗性超声内镜的变革！据波士顿科学新闻稿介绍，AXIOS电切引流支架可用于胰腺假性囊肿和包裹性坏死的引流治疗。它是全球首款可在超声内镜（EUS）引导下使用的管腔贴壁金属支架，这一独特性能使医生可以在术中借助EUS清晰直视以往内镜无法直接接触的解剖部位，从而确保术中穿刺、释放支架过程中定位精准，将可能出现的术中并发症风险降到最低。AXIOS还凭借一体化的支架释放系统，让医生使用一个器械即可完成手术，无需增加或更换支架，告别了以往术中繁复的器械交换过程。此外，因定位精准、操作简易，通常医生从置入至支架释放仅需5分钟，手术效率大幅提升。产品名称：MAGNETOM Lumina全息3T磁共振研发机构：西门子医疗（Siemens Healthineers）获批时间：2021年8月入选评语：全球首台全息仿生成像磁共振，首次实现磁共振的病理级成像，实施360度无死角的病变观察。西门子MAGNETOM全息3T磁共振，开启磁共振精准诊断新时代！据西门子医疗公开资料介绍，MAGNETOM Lumina是全球首台全息3T磁共振，依托西门子医疗磁共振最新技术平台，Lumina 3T搭载了GO 3D全身临床解决方案，实现一键式加速的3D临床解决方案，有望从根本上改变磁共振常规扫描方式，从而更进一步帮助临床决策。产品名称：蜻蜓眼DFVision三维电子腹腔内窥镜研发机构：微创机器人获批时间：2021年6月入选评语：首批获批上市的国产三维电子腹腔镜，自主研发的双路图像采集，填补中国三维电子腹腔镜领域空白。蜻蜓眼，助力腹腔镜手术迈向国际水准！根据微创机器人公司公开资料介绍，蜻蜓眼DFVision可广泛应用于胸科、普外科、妇科与泌尿科等临床科室。与传统二维腹腔镜相比，其通过双路图像采集的方式，为术者提供手术视野的三维立体感和手术操作的纵深感，为术者在腹腔镜下完成快速精细定向操作，如手工缝合、吻合及功能重建、持针器械的换手、打结等提供非常重要的帮助。产品名称：眼底照相机 CLARUS 500研发机构：卡尔蔡司医疗（Carl Zeiss Meditec）获批时间：2021年1月入选评语：全球首台真彩高清超广角眼底照相机，集聚真彩、高清、超广角三大优势，捕获清晰准确图像。CLARUS 500，为眼底病变诊断带来新突破！据卡尔蔡司医疗公开资料介绍，CLARUS 500是一台能够同时提供真实眼底色彩和高分辨率的超广角眼底照相机，可捕获从眼底后极部到周边部达7um的高分辨率图像，让医生能够用真实色彩进行诊断。产品名称：慈孚植入式左心室辅助系统研发机构：同心医疗获批时间：2021年11月入选评语：中国首个拥有完备自主知识产权的国产人工心脏，仅乒乓球大小，突破性解决了血液相容性难题，提高患者生活质量。慈孚VAD，中国心，中国造！据同心医疗新闻稿介绍，慈孚植入式左心室辅助系统是一款全磁悬浮人工心脏，主要应用于治疗终末期重度心衰患者，为晚期难治性左室心力衰竭患者提供血流动力支持。临床研究表明，该产品在血液相容性、植入侵犯性、防感染性等关键性能指标上呈现出全面优势。产品名称：妙手手术机器人研发机构：威高手术机器人获批时间：2021年10月入选评语：中国首台具有自主知识产权的手术机器人，世界上首台完成5G远程腹腔镜手术的手术机器人。妙手机器人，在手术机器人领域树起国产大旗！据威高手术机器人公司公开资料介绍，妙手是中国境内首个获批的腔镜手术机器人，用于胆囊切除术、腹股沟疝手术、食道裂孔疝修补及胃底折叠术、肝囊肿开窗术、阑尾切除术和袖状胃切除术。该产品有利于减少手术并发症，提升患者生活质量，同时还可缓解医生疲劳。产品名称：8301型临时起搏器研发机构：先健心康获批时间：2021年4月入选评语：中国首个拥有完全自主知识产权的临时心脏起搏器，独特的起搏和分析二合一功能。先健心康8301型临时起搏器，从“功能机”带入“智能机”的重大变革！根据先健心康公开资料，8301型临时起搏器既可用于心动过缓患者的临时起搏治疗，也可作为一台起搏系统分析仪使用，对起搏系统的阻抗和感知幅值进行实时连续测量和显示。它不仅实现临时起搏与起搏分析功能二合一，还有其独创的腔内心电图、起搏占比等功能，方便医生观察损伤电流，为精准撤机提供准确数据支持，为医生与患者带来了非常多的便捷。产品名称：“雅客智慧”种牙机器人研发机构：雅客智慧获批时间：2021年9月入选评语：具有自主知识产权的中国首创口腔种植牙机器人，精准、高效、微创。雅客智慧口腔种植手术机器人，开启智慧种牙时代！根据雅客智慧公开资料介绍，“雅客智慧”种牙机器人是一台自主式种牙手术机器人，用于成人口腔种植手术过程中种植体的导航定位。该产品的核心技术包括空间映射、手术路径规划和手术路径定位，临床优势主要为保证种植体植入精度。参考资料：[1]重磅！第十四届健康中国论坛公益榜单发布！. Retrieved Aug 3 , 2022. From https://mp.weixin.qq.com/s/jMQpZvYzQmc51qBhXkM2MQ[2]各公司官方资料及公开新闻稿本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈。转发授权请在「医药观澜」微信公众号留言联系我们。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。